Results 51 to 60 of about 1,084 (158)

Mechanochemical Degradation of Active Pharmaceutical Ingredients (APIs): A Simple Tool for the Prediction of Drug Stability [PDF]

open access: yes
Knowledge of the potential degradation products of active pharmaceutical ingredients (APIs) is of major interest for the development and approval of new drugs. Therefore, methodologies for the time-efficient and precise prediction of degradation products
Amer, Mostafa M.   +6 more
core   +2 more sources

Regulation of TP thromboxane receptor expression and activity by selective P2Y12 receptor antagonists:consequences for dual antiplatelet therapy? [PDF]

open access: yes, 2023
Platelets are small anucleate cells which play a fundamental role in haemostasis restricting blood loss following vessel injury. They also play a critical role in arterial thrombus formation in acute coronary syndromes (ACS).
Keith, Michael R W
core  

Desenvolvimento e validação de métodos analíticos para determinação de prasugrel em comprimidos revestidos [PDF]

open access: yes, 2013
A ativação e agregação plaquetária desempenham papel central na fisiopatologia das síndromes coronarianas agudas (SCA) e complicações após intervenções coronárias percutâneas (ICP).
Rigobello, Camila
core  

Bazı yeni triazol türevlerinin sentezi ve biyolojik aktivilerinin incelenmesi [PDF]

open access: yes, 2015
In the present study 15 novel triazole compounds were synthesized in order to investigate their anticandidal and anticholinesterase activities. Structures of the synthesized compounds were elucidated by spectral data and elemental analyses.
Abu Mohsen, Usama   +4 more
core   +1 more source

Virtual Screening for Potential New Chemotherapeutic Agents for the GPR119 Receptor, a Target for Type II Diabetes [PDF]

open access: yes, 2021
Three frames from a molecular dynamics simulation run of a GPR119 receptor homology model were used for this study. The homology model was validated by virtually screening 76 known GPR119 receptor. 85% of these agonists bound to the receptor.
Bravo, Jennifer Lizeth
core   +1 more source

Prasugrel Metabolites Inhibit Neutrophil Functions s [PDF]

open access: yes, 2020
Clopidogrel and prasugrel belong to a thienopyridine class of oral antiplatelet drugs that, after having been metabolized in the liver, can inhibit platelet function by irreversibly antagonizing the P2Y 12 receptor. Furthermore, thienopyridines influence
Analia E Garcia   +6 more
core  

Rational Design of Pharmaceutical Salt Formulations by Understanding the Mechanism of Disproportionation [PDF]

open access: yes, 2018
Salt forms of the active pharmaceutical ingredient (API) are commonly encountered in the pharmaceutical industry. About half of marketed pharmaceutical products contain the salt form of the API.
Patel, Mitulkumar A.
core   +1 more source

QUANTITATIVE DETERMINATION OF CLOPIDOGREL BISULFATE USING VALIDATED SPECTROPHOTOMETRIC METHODS [PDF]

open access: yes, 2020
A selective, simple and sensitive spectrophotometric methods were introduced for the quantification of Clopidogrel bisulfate (CLPB); an antiplatelet agent widely utilized in the prevention of ischemic stroke, in its raw material and pharmaceutical ...
ISSA, YOUSRY MOUSTAFA   +2 more
core   +1 more source

Classification of medicinal drugs and driving : coordination and synthesis report [PDF]

open access: yes, 2011
In total, 16 systems were found (table 9). Some of these systems are no true categorization systems: Germany directly reproduced ratings from Wolschrijn, and 5 systems have not defined categories (Greece, the Netherlands, Norway, Denmark and Finland ...
Fierro Lorenzo, María Inmaculada   +3 more
core  

Reporting Of Results In Clinicaltrials.gov And High-Impact Journals: A Cross-Sectional Study [PDF]

open access: yes, 2015
In 2007, the FDA Amendments Act expanded requirements for ClinicalTrials.gov, a public clinical trial registry maintained by the U.S. National Library of Medicine, mandating results reporting within 12 months of trial completion for all FDA regulated ...
Becker, Jessica Elizabeth
core   +1 more source

Home - About - Disclaimer - Privacy